This study was designed to clarify the role of endogenous Bcl-x L expression in modulating apoptosis of malignant cells. Administration of bcl-x-antisense oligonucleotides decreased Bcl-x L protein levels in the MKN-45 human gastric cancer cell line. The decrease in Bcl-x L protein content resulted in increased cell death induced by serum deprivation or Fas-antibody administration. Flow cytometric analysis revealed that the increased apoptotic cell death was more prominent in bcl-x-antisense-treated cells as compared to control cells, bcl-x-sense-treated cells, or bcl-x-nonsense-treated cells. To inhibit the eect of intrinsic Bcl-x L protein, we overexpressed Bak, which binds Bcl-x L and inhibits the anti-apoptotic eect of Bcl-x L , by transfection into MKN-45 cells. Bak-overexpressing cells showed increased apoptotic cell death induced by Fas-antibody when compared to parent cells and MKN-neo-transfected cells. Bak-overexpressing cells also showed greater sensitization to 5-¯uorouracil and cisplatin than parent cells and MKN-neo-transfected cells.
Introduction
Homeostasis of gastrointestinal mucosa is maintained by a balance between the growth and apoptosis of mucosal cells. Apoptosis is critical not only in tissue homeostasis, but also in the pathogenesis of a variety of diseases including cancer, autoimmune disease, viral infection, and neurodegenerative disorders.
The Bcl-2 family of proteins plays a central role in the regulation of apoptotic cell death induced by a wide variety of stimuli (Reed, 1994 (Reed, , 1997 . A member of the bcl-2 related family of genes, bcl-x encodes two proteins in human, a long form (Bcl-x L ) and a short form (Bcl-x S ), derived through alternative splicing mechanisms (Boise et al., 1993) . The Bcl-x L protein displays remarkable amino-acid and overall structural homology to Bcl-2, and it also inhibits apoptosis as eectively as Bcl-2 protein. On the other hand, Bcl-x S protein, which lacks 63 amino-acids contained within Bcl-x L blocks the death-suppressor activity of Bcl-2 (Boise et al., 1993) . Although details about the biochemical functions of Bcl-x L has not been clari®ed, recent study has shown that the three-dimensional structure of Bcl-x L is similar to the structure of the pore-forming domains of bacterial toxins that act as channels for either ions or proteins (Muchmore et al., 1996) . Furthermore, it has been shown that Bcl-x L forms an ion-conducting channel in synthetic lipid membranes (Minn et al., 1997) .
In the stomach, Bcl-x immunoreactivity has been observed in dierentiated mucosal cells including mucosal cells, parietal cells, and chief cells (Krajewski et al., 1994) . Furthermore, Bcl-x L has been shown to be the major form of Bcl-x in the gastrointestinal tract (Krajewski et al., 1994; Kondo et al., 1996) . We previously have demonstrated that the bcl-x L gene is overexpressed in human gastric adenomas and carcinomas (Kondo et al., 1996) . However, it has not been clari®ed whether endogenous Bcl-x L expression in tumor cells is involved in resistance to apoptotic stimuli.
Recently, bak (Bcl-2 homologous antagonist / killer) has been cloned as a bcl-2 related gene. The bak gene encodes a 211-amino acid protein with a relative molecular mass (Mr) of 23.4 K. Gene transfermediated elevations in Bak protein levels accelerate apoptosis induced by growth factor deprivation in murine lymphoid, neuronal, and ®broblastic cells (Chittenden et al., 1995b; Farrow et al., 1995; Kiefer et al., 1995) , suggesting that Bak functions primarily as a promoter of apoptosis. The Bak protein has been shown to bind to the antiapoptotic protein Bcl-x L , but does not appear to dimerize with Bcl-2, Bcl-x S , Bax, or with itself (Farrow et al., 1995) . It has been reported that mutations in Bak that eliminate heterodimerization with Bcl-x L abrogate the ability of Bak to induce cell death (Chittenden et al., 1995a) . These observations suggest that Bak increase apoptosis through binding with bcl-x L which inhibits the anti-apoptotic eect of bcl-x L .
This study was designed to clarify the role of endogenous Bcl-x L expression in tumor cells. We found that inhibition of bcl-x L production by bcl-xantisense enhances the sensitivity of human gastric cancer MKN-45 cells to apoptosis induced by serum deprivation or by the Fas signal. Furthermore, we demonstrated that ectopic expression of Bak sensitizes cells to Fas-and chemotherapy-induced apoptosis.
Results

Evaluation of Bcl-x L protein levels by Western blotting
The Bcl-x L protein was detected as a doublet with a molecular weight ranging from 29 ± 31 kDa, a ®nding consistent with previous reports (Krajewski et al., 1994) . When added to cultures of MKN-45 cells for 4 days, bcl-x-antisense produced concentration-dependent reductions in the steady-state levels of Bcl-x L protein (Figure 1 ). In contrast, the Bcl-x L protein level of 50 mM bcl-x-sense-treated or 50 mM bcl-xnonsense-treated cells was similar to that of untreated cells. This eect of the bcl-x-antisense was speci®c, because level of the control Actin protein was unchanged. A 19 kDa band which would correspond to the Bcl-x S protein was not detected in control, bcl-xantisense-treated, bcl-x-sense-treated, or bcl-x-nonsense-treated cells (Figure 1 ).
Eect of antisense oligonucleotides to bcl-x on cell survival after serum deprivation After preincubation with 50 mM bcl-x-antisense, bclx-sense or bcl-x-nonsense oligonucleotides for 4 days, serum was removed from the medium. Pretreatment with antisense oligonucleotides rapidly decreased the number of viable cells after serum deprivation in a time-dependent manner ( Figure 2) . Although sense or nonsense oligonucleotides showed limited toxicity, sense-treated or nonsense-treated cells survived for more than 4 days after serum deprivation.
Eect of antisense oligonucleotides to bcl-x on Fas-induced apoptosis
The Fas antigen was detected in MKN-45 cells as an apparent single band with a molecular weight of 45 kDa (Figure 3a) . Treatment for 4 days with bcl-xantisense, bcl-x-sense, or bcl-x-nonsense oligonucleotides did not aect Fas antigen expression. At concentrations of the CH-11 Fas antibody ranging from 25 ± 100 ng/ml, antisense-pretreated cells demonstrated markedly increased cytopathic eects as compared to control, sense-pretreated and nonsensepretreated cells exposed to equivalent concentrations of the Fas antibody (Figure 3b ). In order to determine if increased sensitivity to Fas antibody treatment in antisense-pretreated cells could be attributed to apoptosis, the number of apoptotic cells was measured by¯ow cytometry. Fragmented DNA contained in apoptotic cells resulted in an unequivocal hypodiploid DNA peak that was distinguishable from the diploid DNA peak seen in MKN-45 cells treated with 100 ng/ ml Fas antibody (Figure 4a ). The increase in apoptotic cells induced by Fas antibody was more prominent in bcl-x-antisense-pretreated cells than control cells, bcl-xsense-pretreated or bcl-x-nonsense-pretreated cells (Figure 4b ).
Expression of Bak, Bcl-2, Bcl-x and Bax protein in bak-transfected MKN-45 cells Bak protein has been shown to bind Bcl-x L protein and inhibit the anti-apoptotic eect of Bcl-x L (Chittenden et al., 1995a,b; Farrow et al., 1995; Kiefer et al., 1995) . In order to inhibit the eect of intrinsic Bcl-x L protein, we transfected bak gene into MKN-45 cells. The expression of Bak protein in MKN-neo and MKN-bak cells was assessed by Western blotting using a Bak monoclonal antibody speci®c for Bak protein. The Bak protein was detected as a single band with a molecular weight of *24 kDa (Figure 5a ), consistent with ®ndings of previous studies (Krajewski et al., 1996) Table 1) .
Eect of bak overexpression on chemosensitivity of MKN-45 cells to 5-FU and cisplatin
We next examined the sensitivity of MKN-neo-and bak-transfected cells to 5-¯uorouracil (5-FU) and cisplatin treatment. Bak-overexpressing cells showed increased cytopathic eects of 5-FU as compared to parent cells and MKN-neo-transfected cells (Figure 7a ). Cells transfected with bak also exhibited increased sensitivity to cisplatin treatment (Figure 7b ). After administration of 5-FU and cisplatin, the percentage of apoptotic cells in MKN-bak cells was higher than that of parent cells or MKN-neo cells (Figure 7c ). Several Bak-overexpressing clones showed similar sensitivity to 5-FU and cisplatin (Table 1) .
Discussion
Bcl-x L , a member of the Bcl-2 family, has been shown to be expressed by a number of tumors including those of the gastrointestinal tract (Kondo et al., 1996 , Krajewska et al., 1996a . Although in vitro studies have demonstrated that transfection-enforced hyperexpression of bcl-x L prevents apoptosis in response to a wide variety of stimuli, it has not been determined if endogenous Bcl-x L present in tumor cells is involved in resistance to apoptosis. This study was designed to clarify the role of endogenous Bcl-x L expression in modulating apoptosis of tumor cells.
We studied the eect of bcl-x-antisense oligonucleotides on the sensitivity of MKN-45 human gastric cancer cells, which intensely express Bcl-x L protein, to apoptosis. Administration of bcl-x-antisense apparently decreased Bcl-x L protein levels in this cell line. On the other hand, Bcl-x S protein, an alternative-splicing variant of Bcl-x L , was not detected in these cells. The decrease in Bcl-x L protein content in antisense-treated cells was followed by rapid cell death following serum deprivation. Although limited toxicity of sense or nonsense oligonucleotides was observed, sense-treated or nonsense-treated cells survived for more than 4 days despite removal of medium serum. Furthermore, we examined the eect of bcl-x-antisense on the sensitivity of cells to Fas-mediated apoptosis. Fas is a 45 kDa cell surface proteins that mediates apoptosis in a variety of cell types (Trauth et al., 1989; Yonehara et al., 1989; Itoh et al., 1991; Oehm et al., 1992; Ogasawara et al., 1993) . Fas is expressed by several tumor, including gastric cancers (Hayashi et al., 1997) . Western blot analysis demonstrated intense expression of Fas antigen in MKN-45 gastric cancer cells. The level of Fas antigen expression was not aected by antisense, sense, or nonsense oligonucleotides. Antisense-pretreated cells produced markedly increased cytopathic eects as compared to control, sense-pretreated or nonsense-pretreated cells exposed to equivalent concentrations of the Fas antibody. Flow cytometric analysis revealed that apoptotic cell death was more prominent in bcl-x-antisense-treated cells than in control, bcl-x-sense-treated or bcl-x-nonsense-treated cells. Our results demonstrating that decreases in Bcl-x L protein promotes cell death in response to serum deprivation or Fas-antibody administration suggest that endogenous Bcl-x L expression is important in resistance of malignant cells to apoptosis.
To further examine the role of Bcl-x L expression in cancer cells, we transfected the bak gene into the MKN-45 cell line. Western blot analysis revealed that overexpression of Bak does not aect the expression of other Bcl-2 family proteins. We also showed that overexpression of Bak sensitizes cells to Fas-induced apoptosis. Bak protein has been shown to interact with Bcl-x L , but not to dimerize with Bcl-2, Bcl-x S , or Bax in a yeast two-hybrid system (Farrow et al., 1995) . It has been reported that mutations of Bak that eliminate heterodimerization with Bcl-x L abrogate the ability of Bak to induce apoptotic cell death (Chittenden et al., 1995a) . These observations suggest that ectopic expression of Bak promotes Fas-mediated apoptosis by antagonizing the anti-apoptotic eect of endogenous Bcl-x L . Recently, it has been reported that Fas is upregulated by p53, a potent tumor suppressor gene (Owen-Schub et al., 1995) . It has also been shown that the loss of Fas accelerates lymphomagenesis in Em L-myc transgenic mice (Zornig et al., 1995) . Furthermore, Fas-induced apoptosis is impaired in hepatocytes derived from transgenic mice that express the SV40 Tantigen in liver and subsequently develop hepatocellular carcinoma (Rouquet et al., 1995) . These observations suggest that the Fas pathway is important in inhibiting tumorigenesis. Overexpression of Bcl-x L has been demonstrated in a number of tumors, including gastric carcinomas (Kondo et al., 1996; Krajewska et al., 1996a) . Recently, it has been reported that ectopic expression of Bcl-x L enhances radiation-induced mutagenesis in human lymphoblastoid cell lines (Cherbonne-Lasserre et al., 1997). These observations and our ®nding that inhibition of intrinsic Bcl-x L by antisense oligonucleotides or ectopic bak expression sensitizes cells to Fas-mediated apoptosis suggest that resistance to Fas-mediated apoptosis by endogenous bcl-x L overexpression may be a critical component in tumorigenesis and/or tumor progression.
Defects of apoptosis are important not only in tumorigenesis, but also in the treatment of cancer. A number of chemotherapeutic agents have been shown to destroy tumor cells through apoptosis (Eastman, 1990) . Gastric cancers are poorly responsive to chemotherapy, suggesting that these tumors are intrinsically resistant to the apoptosis-inducing eects of available agents. Apoptosis regulating genes, including p53, bcl-2 and bcl-x L , have been shown to aect the sensitivity of cancer cells to chemotherapy (Kamesaki et al., 1993; Lowe et al., 1993; Dole et al., 1994; Sumantran et al., 1995) . In vitro studies have demonstrated that transfection-enforced hyperexpression of bcl-x L results in resistance to various anticancer drugs (Minn et al., 1995) , suggesting that bcl-x L can inhibit chemotherapy-induced apoptosis. In this report, we demonstrated that overexpression of Bak in MKN-45 cells sensitizes these cells to injury by low concentrations of 5-FU or cisplatin. Although both 5-FU and cisplatin are often utilized in the treatment of gastric cancer, these agents have only limited ecacy. Development of therapeutic agents that target the Bcl-x L -mediated pathway could provide rational new treatment of gastric cancer.
The intracellular mechanisms responsible for the inhibitory action of Bcl-x L on Fas-and chemotherapyinduced apoptosis have not been clari®ed. Recently, it has been shown that Bcl-x L expression does not block Fas-induced activation of interleukin-1b-converting enzyme (ICE)/Ced-3 protease, but does inhibit the The percentage of apoptotic cells were calculated by¯ow cytometry as described in Figure 4 . Data are expressed as means+s.e. (n=3) subsequent loss of mitochondrial membrane potential and cell death in Fas-treated cells (Boise and Thompson, 1997) . Furthermore, Bcl-x L overexpression has also been shown to antagonize the mitochondrial dysfunction that precedes nuclear apoptosis induced by chemotherapeutic agents (Decaudin et al., 1997) . These observations suggest that Bcl-x L can maintain cell viability by preventing the loss of the mitochondrial membrane potential induced by apoptotic stimuli.
In conclusion, we demonstrated that bcl-x-antisense oligonucleotides or overexpression of Bak protein induces sensitization to apoptosis in MKN-45 gastric cancer cells, suggesting that endogenous Bcl-x L expression in cancer cells plays an important role in modulating apoptosis.
Materials and methods
Reagents
Cisplatin and 5-FU were purchased from Sigma (St Louis, MO, USA). The mouse anti-bak, rabbit anti-bax, rabbit anti-bcl-x, and goat anti-actin antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and the mouse anti-bcl-2 antibody was purchased from Dako (Kyoto, Japan). The mouse Fas antibody used for West-ern blotting was kindly provided by Dr Shigekazu Nagata (Osaka University Medical School, Osaka, Japan). Fas antibody (CH-11), which induces apoptosis in Fas expressing cells, was purchased from MBL (Nagoya, Japan).
Antisense oligonucleotides
High-performance liquid chromatography (HPLC)-puri®ed 20-mer bcl-x antisense oligonucleotides, complementarysense oligonucleotides and nonsense (a scrambled version) oligonucleotides were purchased from Bex (Tokyo, Japan). The antisense oligonucleotides straddled the predicted translation-initiation site of human bcl-x mRNA. The sequences used were 5'-CCCGGTTGCTCTGAGACATT-3' (bcl-x-antisense), 5'-AATGTCTCAGAGCAACCGGG-3' (bcl-x-sense) and 5'-AAGTCGAGCCTCCTCGTTGT-3' (bcl-x-nonsense).
Cells and cell culture
Human gastric cancer MKN-45 cells were cultured in RPMI 1640 supplemented with 10% heat-inactivated fetal calf serum (Whittaker Bioproducts, Walkersville, MD, USA), 100 units/ml penicillin, and 100 mg/ml streptomycin in a water-saturated atmosphere containing 5% CO 2 at 378C.
Transfection of the bak gene
The bak cDNA which was inserted into the expression vector pcDNA I was kindly provided by Dr R Brown (Glaxo Research and Development Ltd, Greenford, UK). The bak-transfected MKN-45 cell clones (MKN-bak-1, MKN-bak-2 and MKN-bak-3) were created by transfecting the mammalian expression vector encoding bak under the control of the simian virus 40 early gene promoter of pSV2neo, which contains the neomycin resistance gene, by co-transfection with lipofectamine reagent (GIBCO, MD) according to the manufacturer's instructions. The transfected cells were selected by growth in a medium containing 500 mg/ml of G418 (GIBCO). Cell clones were obtained from individual G418-resistant colonies with cloning rings. Control cells (MKN-neo) were created by transfecting only the neo resistance gene to MKN-45 cells.
Western blot analysis
Cells were washed in PBS and lysed in lysis buer containing 20 mM Tris (pH 8.0), 137 mM NaCl, 10% glycerol, 1% Nonidet P-40, 10 mM EDTA, 100 mM NaF, 1 mM PMSF, 0.25 TIU/ml of aprotinin, and 10 mg/ml of leupeptin. Aliquots containing 30 mg of total protein were size-fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (14% gels). Immunoblot analysis was performed as previously described using a mouse anti-Bak, rabbit anti-Bax, mouse anti-Bcl-2, rabbit anti-Bcl-x, mouse anti-Fas, or goat anti-Actin antibody (Kondo et al., 1996) . Protein concentrations of the homogenates were determined using a bicinchoninic acid protein assay reagent (Pierce, Rockford, IL, USA).
Number of viable cells and cell viabilities
MKN-45, MKN-bak, and MKN-neo cells were cultured in medium lacking G418. Cells were plated in 12-well plates (10 4 well) and treated with varying doses of Fas-antibody (CH-11), 5-FU, or cisplatin. Excluding serum deprivation studies, experiments were performed under 10% FCSsupplemented conditions. The number of viable cells was determined by hemocytometry using trypan blue exclusion.
Measurement of apoptosis by¯ow cytometry
DNA degradation in response to each stimuli was assessed by measuring the DNA content of individual cells by¯ow cytometry. In preparation for¯ow cytometry, cells were collected after brief trypsinization, washed with PBS, and ®xed in 70% cold ethanol. Samples then were treated with RNase, stained with 10 mg/ml propidium iodine, and analysed using a Becton Dickinson FACScan. Cell cycle distributions were quanti®ed using Cell-quest software. The number of DNA fragmented cells were determined as the subdiploid fraction and the percentage of apoptotic cells was calculated.
